Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…sions Diastolic dysfunction was as common in pre-diabetes as in diabetes and was mainly associated with central adiposity, hypertension …
…Background Attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) often coexist. ADHD com…
…arbital remains the first-line therapy in our NICU, followed by levetiracetam. Lidocaine has proven to be an effective and safe third-line th…
…umab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent pati…
…ic impact of implementing the protocol.Material and Methods All migraine medication prescriptions between March 2023 and March 2025 were…
…n differences were found in patients treated with dabigatran or edoxaban.It would be advisable for regulatory agencies to issue clear re…
…ed in 81% (N=13) of treatments: 2 atogepant, 1 erenumab, and 10 fremanezumab. A mean of 11 MMDs and 52 HIT6 score were recorded at beginning…
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
…owel syndrome), Regulora (Irritable bowel syndrome), AspyreRx™ (Type 2 diabetes). Their main therapeutic modality is based on cognitive behavio…
…es (age 15–30 years, Tier ≥2) with DXA scans were classified as AMEN (n=159), OLIGO (n=84) or naturally menstruating (NM, n=145) usi…
…nd PDDI (OR=4.51, 95% CI 3.05 to 6.69, p<0.01, I2=0.00%), while hypertension (OR=2.46, 95% CI 1.38 to 4.36, p<0.01 I2=0.00%) was associated …
…posure and the need for rescue therapies. Early optimisation of SLE management and effective disease control may also lead to great…